Read Our Latest Issue Most cancer patients never get into lifesaving drug trials because of barriers at community hospitals Jean Reimers, a 75-year-old retired supermarket cashier, enjoys her life in Grand Island, Neb., a small city near the Platte River that boasts attractions such as the Stuhr Museum of the Prairie Pioneer and a sandhill crane nature reserve. Nearly two years ago Reimers found out from her local doctor that she had cancer. The worse news was that it was late-stage metastatic lung cancer, hard to treat and with a dismally low survival rate. The standard approach in such cases is palliative care to keep dying patients comfortable. "It looked like I probably wouldn't be around another year," she says. This is a preview. Make a selection below to access this issue.Already have access? . Having trouble accessing this article? Please visit our page for more information Discover world-changing science. Explore our digital archive back to 1845, including articles by more than 150 Nobel Prize winners. Follow us Scientific american arabic (c) 2021 Scientific American, a Division of Springer Nature America, Inc. All Rights Reserved. Support our award-winning coverage of advances in science & technology. Already a subscriber? Subscribers get more award-winning coverage of advances in science & technology.